US Edition
# Biocryst Pharmaceuticals Between Milestones and Market Trials,
Summary by csimarket.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
# Biocryst Pharmaceuticals Between Milestones and Market Trials,
Biocryst Pharmaceuticals Inc. (NASDAQ: BCRX) has recently achieved a significant regulatory milestone with the approval of ORLADEYO (berotralstat) in Colombia. This approval marks an important step in expanding treatment options for patients suffering from hereditary angioedema (HAE), a rare genetic condition that causes recurrent episodes of severe swelling. Despite this positive development, as of now, Biocryst's share price stands at $10.4, r…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
